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Introduction. The results obtained with dynamic PET (dPET) were compared to gene expression data obtained in patients with
gastrointestinal stromal tumors (GIST). The primary aim was to assess the association of the dPET results and gene expression
data. Material and Methods. dPET was performed following the injection of F-18-ﬂuorodeoxyglucose (FDG) in 22 patients with
GIST. All patients were examined prior to surgery for staging purpose. Compartment and noncompartment models were used for
the quantitative evaluation of the dPET examinations. Gene array data were based on tumor specimen obtained by surgery after
the PET examinations. Results. The data analysis revealed signiﬁcant correlations for the dPET parameters and the expression of
zincﬁngergenes(znf43,znf85,znf91,znf189).Furthermore,thetransportofFDG(k1)wasassociatedwithVEGF-A.Thecellcycle
gene cyclin-dependent kinase inhibitor 1C was correlated with the maximum tracer uptake (SUVmax) in the tumors. Conclusions.
The data demonstrate a dependency of the tracer kinetics on genes associated with prognosis in GIST. Furthermore, angiogenesis
and cell proliferation have an impact on the tracer uptake.
1.Introduction
Gastrointestinal stromal tumors (GIST) are rate tumors
arising in the gastrointestinal tract. Imatinib mesylate (ima-
tinib) is frequently used in these patients for treatment.
However, the resection of the tumor is the primary aim
of treatment. Frequently, mutations are noted in the kit
or platelet-derived growth factor receptor-A (PDGFRA).
The expression of genes and their possible mutations are
important for treatment of GIST. The survival is primarily
correlated with the stage of disease, the tumor size, and
the proliferation. Rutkowski et al. diﬀerentiated the GIST
according to location and stage and reported about a 5-year
survival rate in gastric GIST of 96% for stage IA, 92% for IB,
51% for II, 22% for IIIA, and 22% for IIIB [1]. Setoguchi
et al. evaluated the prognostic aspect of gene array data in
GIST[2].TheauthorswereabletoshowthatVCANandCD9
are prognostic markers in gastric GIST. Disease-free survival
was signiﬁcantly longer for patients if CD9 was enhanced
andexpressed,andVCANrevealedalowexpression.Another
study by Schmieder et al. demonstrated that p16 is also
important for the identiﬁcation of high-risk GIST and p16
was predictive for poor outcome [3] .T h el i t e r a t u r er e s u l t s
demonstrate that quantitative data about the expression of
genes may be helpful to gain prognostic information.
Positron emission tomography (PET), in particular PET-
CT, can be used to obtain accurate information about the
distribution of a tracer over time within a given volume if a
dynamicacquisition,forexample,foronehourisperformed.
Dynamic PET (dPET) and PET-CT (dPET-CT) data can be
analyzed by applying compartment and non-compartment
models to achieve detailed information about the tracer
kinetics.2 The Scientiﬁc World Journal
F-18-deoxyglucose (FDG) is the most commonly used
tracer for PET in oncology. The tracer kinetics of FDG is
closely dependent on the expression of glucose transporters
and hexokinases. However, it was shown that the kinet-
ics of FDG may be modulated by genes associated with
angiogenesis and proliferation [4, 5]. Thus, gene expression
may be predicted from a detailed analysis of the FDG
kinetics in certain tumors. However, no data exist about the
correlationofgeneexpressionandquantitativedynamicPET
datainGIST.Therefore,theaimofthisstudywastoassessthe
association of FDG kinetics and gene expression in GIST.
2.MaterialandMethods
The study comprises 22 patients with GIST scheduled for
surgery. Dynamic PET studies were performed prior to
surgery within the routine diagnostics for tumor staging.
All patients had pretreatment with imatinib, and surgery
was intended to remove the tumor tissue. The body volume
for the dynamic study had been determined according to
the clinical information where the surgery was performed.
Following the intravenous injection of 200–300MBq FDG,
a dynamic data acquisition was initiated for one hour.
Then whole body imaging was performed following the
dynamic study. The dynamic study comprises 28 frames,
including 10 frames of 30s, 5 frames of 60s, 5 frames of
120s, and 8 frames of 300s. Following the iterative image
reconstruction, the images were converted to standardized
uptake value (SUV) images for further evaluation. The SUV
was calculated according to the following: SUV = tissue
concentration (Bq/g)/(injected dose (Bq)/body weight (g)
[6].
In 20 of the 22 patients the dynamic studies could be
evaluated using a 2-tissue-compartment model. Volumes of
interest (VOI) were used for the quantitative assessment of
the tumors. The quantitative evaluation was performed with
a dedicated software and included the calculation of SUV
and the maximum SUV. Furthermore, the tracer kinetics
was analyzed using a 2-tissue-compartment model. For this
purpose a VOI was placed over the descending aorta to
obtain an input function for the model. It was already shown
by Ohtake et al. that the input data for FDG can be obtained
v i aV O I sf r o mal a r g ev e s s e lw i t hh i g ha c c u r a c y[ 7]. The
authorsnotedamedianerrorof3.75%fortheimage-derived
results as compared to the arterial sampling data. No partial
volume correction was needed, because the diameters of
the vessels exceeded 8mm, which correlates with a recovery
factor of 0.85 for our system and the image reconstruction
settings used for the study. The compartment analysis
software provides ﬁve parameters: k1 and k2, associated
with the transport of FDG; k3 and k4, which are associated
with the phosphorylation and dephosphorylation; vb, the
fractional blood volume of a VOI, also referred to as vessel
density.Furthermore,anoncompartmentmodelwasapplied
to the data to obtain the fractal dimension (FD) of the
time activity data. The positioning of the VOIs was done
accordingtotheinformationprovidedbythesurgeonsabout
the location, where the tissue specimen was removed from
the tumor. Thus, we tried to get the quantitative dPET data
spatially close to the region where the tissue specimen was
obtained.
Tumor resection was performed in the 22 patients. A
small fraction of the tumor was used for gene array analysis.
The tissue specimens were immediately stored in liquid
nitrogen,andtotalRNAwasextractedforfurtherprocessing.
The quality of isolated RNA was evaluated photometrically
using the 280/260 ratio and on an agarose gel. We used the
U133A 2.0 gene array (Aﬀymetrix Inc., Santa Clara, CA,
USA), which provides quantitative information about 54675
gene probes. The processing of the RNA and gene arrays
wasdoneaccordingtothemanufacturer’srecommendations.
Gene chip expression data were normalized for the beta-
2 microglobulin (Aﬀymetrix code 34644 at, Homo sapiens
mRNA for beta-2 microglobulin) using the following equa-
tion: relative expression value (REV) = 1,000×expression
value of a gene/expression value for beta-2 microglobulin
[8].
The statistical evaluation was performed with Stata/SE
11.2 (Stata Corporation, College Station, TX, USA) on a
Mac Pro 2 × 2.93GHz, 12 Core Intel Xeon system with
24GB RAM using Mac OS X 10.7.3 (Apple, Cupertino, CA,
USA). The same system was also used for all data processing
tasks, including dPET and gene array data. A dedicated
software (GenPET), developed by our group, was used for
the correlative evaluation of dynamic PET and gene array
data [9]. The software provides the correlative assessment
of both PET and gene array data. For the correlation
analysis, a signiﬁcance level of P<0.05 was used. Based on
the signiﬁcant results of the correlation analysis, nonlinear
regression functions were calculated for the gene array and
PET data.
3. Results
The statistical data for the PET parameters are provided in
Table 1. The mean SUV was 6.597, nearly half of the SUVmax.
The fractional blood volume (vb), associated with the vessel
density, was 0.108, which reﬂects about 11% of the tumor
volume evaluated by VOIs. The maximum vb was 0.253,
which refers to a blood volume fraction of about 1/4 of the
tumor volume. As expected, k1 (FDG transport) was high,
and k3 (FDG phosphorylation) was relatively low in these
tumors.
Several studies are focused on the gene expression
patterns in GIST. Rink et al. compared the gene expression
signatures with the response to imatinib mesylate treatment
in 63 patients [10]. Overall, the authors report about 38
genes, which were expressed lower prior to therapy and were
associatedwithresponsetotreatment.Interestingly,18ofthe
38 genes are related to the genes of the zinc ﬁnger group.
The function of all zinc ﬁnger genes is not well known,
but it is likely that they are involved in signaling and cell
regulation mechanisms. Based on the results from Rink et
al., we evaluated the zinc ﬁnger gene data for possible cor-
relations with the PET data. We used a nonlinear regression
approachandcombinationsoftwoorthreePETvariablesfor
the correlation/regression analysis. Signiﬁcant correlations
(r>0.8) were found for znf43, znf85, znf91, and znf189.The Scientiﬁc World Journal 3
Table 1: Statistical data for the PET parameters.
SUV SUVmax vb k1 k2 k3 k4 fd inﬂux
Mean 6.597 13.029 0.108 0.446 0.787 0.070 0.004 1.306 0.036
Median 6.599 12.104 0.066 0.423 0.802 0.067 0.001 1.448 0.030
Minimum 1.406 2.286 0.028 0.199 0.542 0.003 0.000 1.035 0.003
Maximum 16.935 29.280 0.253 0.801 0.928 0.188 0.013 1.448 0.105
































































Figure 1: Correlations and nonlinear regression functions of PET parameters, obtained from the dynamic studies, and gene expression data.
The PET variables used for the nonlinear regression func-
tions are shown on the x-axis in Figure 1, while the y-axis
reﬂectsthecorrespondinggeneexpressiondata(unitforgene
expression data: REV).
Besides the zinc ﬁnger genes, we noted also a signif-
icant diﬀerence for high (>0.441) and low k1 values and
the expression of VEGF-A, an angiogenesis-related gene
(Figure 2). Interestingly, this had been already reported, for
example, for colorectal tumors and gene array data [4].
The cyclin-dependent kinase inhibitor 1C has an impact
on cell proliferation and acts as a tumor suppressor gene.
A correlation (r = 0.85) was noted for this gene and the
maximum SUV (Figure 3).
4. Discussion
InpatientswithGIST,PETwithFDGisacommonprocedure
for both, diagnostic purpose for staging and follow to assess
the response to treatment. Apostolopoulos et al. evaluated 65
dynamic PET-FDG studies in patients with liver metastases
from GIST [11]. He used parametric imaging for the data
evaluation and report about an accuracy of 87.7% and4 The Scientiﬁc World Journal
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Figure 3: Correlation of the maximum SUV with cdki 1C (r = 0.8539).
a sensitivity of 88.2%. Gayed et al. examined 54 patients
with PET-FDG and reported about a sensitivity of 86% [12].





the assessment of FDG dynamic data. One major advantage
of dPET is the possibility to obtain the input function for
the 2-tissue model from the images without arterial blood
sampling. We calculated all ﬁve parameters of the model
using a dedicated software developed by our group. The
software uses a modiﬁed support vector machines algorithm
to calculate the model parameters. The dephosphorylation
rate of FDG may be low in tumors, but we included k4 also
in the model calculations to achieve most accurate results.
One aspect of major importance is the correlation of
PET results with molecular biological data. Park et al.
compared in 26 patients with gastric GIST the maximum
SUV (SUVmax) with the Ki-67 index [13]. The authors
obtained a correlation of r = 0.854 for the two parameters.
Based on our results, the SUVmax was generally enhanced
and above 10 SUV. The compartment data suggested a
primary contribution of vb and k1 to the global FDG
uptake. However, more data are needed to evaluate the
dependency of the global uptake and maximum uptake on
tumor proliferation.
Rink et al. identiﬁed genes, correlated with response to
imatinib mesylate treatment [10]. Most of the genes were
zinc ﬁnger genes. These genes are usually associated with the
regulation of transcription. We noted signiﬁcant correlations
for the PET parameters and ZNF43, ZNF85, ZNF91, and
ZNF189 (Figure 1). Primarily, the SUV and SUVmax were
correlated with the zinc ﬁnger genes. However, SUV and
SUVmax alone correlate only with ZNF189; therefore, the
results from the dPET are required to predict the gene
expression accurately. Rink et al. were able to demonstrate
that a subgroup of zinc ﬁnger genes are predictive for
the treatment outcome in patients treated with imatinib
mesylate [10]. Furthermore, they performed knock down
experiments, for example, with ZNF43, ZNF85, and ZNF91,
and they showed that depletion of each of the ZNFs resulted
in an improved sensitization to imatinib mesylate. Thus,
predicting the expression of these genes from quantitative,
dynamic PET results may be a promising approach for an
improved evaluation of treatment response in GIST.
Besides the zinc ﬁnger genes, other genes, for example,
associatedwithangiogenesis,areimportantforthetreatmentThe Scientiﬁc World Journal 5
results. We noted a signiﬁcant diﬀerence for high and low k1
dataandtheexpressionofVEGF-A(Figure 2).Thediﬀerence
of the two groups is signiﬁcant with P<0.0197. The
same limit for k1 (0.441) was used as in the publication
about colorectal tumors and PET [4]. Therefore, it can
be assumed that k1 is generally modulated by VEGF-A
expression. Overall, tumors with a k1 less than 0.441 had a
lower expression of VEGF-A as compared to tumors with
a higher k1. However, this should be shown also for other
tumortypes,butwecanassumethatthedependencyofk1on
the VEGF-A expression is most likely not dependent on the
tumor type. Thus, k1 may be used as a general classiﬁcation
parameter to predict VEGF-A expression in a malignant
lesion.
The role of the cyclin-dependent kinase inhibitor 1C
(cdki 1C) is described in detail in the review paper of
Kavanagh and Joseph [14]. cdki 1C is involved in several
regulatory processes, including tumor diﬀerentiation and
angiogenesis, apoptosis, cell invasion, and metastasis. The
gene acts as a tumor suppressor gene. Therefore, we noted
a lower expression of cdki 1C with higher SUVmax values
(Figure 3). Actually, no publications exist about cdki 1C and
FDG in PubMed, so it is not possible to compare our results
with others. Actually it can be expected that inhibitors of
the cell cycle usually reveal a negative correlation to PET
parameters. Based on our results in colorectal carcinoma,
we were able to show that cdki 2B was negatively correlated
with k3 [5]. In contrast, cdk2 was positively correlated with
the SUV in these tumors. Overall, the correlation between
cdki 1C and SUVmax is in agreement with the conclusions of
Park et al. who found a correlation for the SUVmax and ki-67
[10]. Thus, the SUVmax is likely to be predictive for tumor
proliferation in GIST.
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